X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Weight-Loss Surgery, Prescriptions More Satisfying for Obese Patients

Yuvraj_pawp by Yuvraj_pawp
9th July 2014
in Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Obese patients who underwent surgery or took medications to lose weight were more satisfied with their results than those who made lifestyle changes.

 

Nearly 60% of obese patients are not taking any action to lose weight, according to the results of a recent analysis of the 2012 National Health and Wellness Survey conducted by Eisai Inc and Kantar Health. The study, presented on June 21, 2014, at the 16th International Congress of Endocrinology and the Endocrine Society’s 96th Annual Meeting and Expo in Chicago, also found that among obese individuals who did attempt to lose weight, those who underwent surgery or took prescription medications were more satisfied with their weight loss than those who made lifestyle modifications.

 

Researchers of the study analyzed the weight-loss satisfaction of 22,927 obese adults and 19,121 obese adults who had at least 1 related comorbidity including type 2 diabetes, hypertension, or dyslipidemia. Patients were categorized as having undergone a weight-loss surgery or using a prescription for weight loss or using self-modifications such as diet, exercise, weight management programs, and over-the-counter medications and supplements to lose weight. Overall satisfaction with current weight-loss methods was analyzed on a scale from 1 (extremely dissatisfied) to 7 (extremely satisfied).

 

Of the 22,927 obese patients included in the analysis, 58.4% were not attempting to lose weight. This result suggests “the need for more education on obesity awareness/prevention,” the authors of the study noted.

 

Only 2.3% of patients used surgery or prescription medications to lose weight, while 39.3% were in the self-modification group. The results indicated that patients who used surgery or medications were significantly more satisfied with their weight-loss methods than those who made lifestyle changes. Among obese patients who had weight-loss surgery or took medications, 39.3% reported being extremely or very satisfied, compared with just 20.2% of modification patients. Similar results were observed among obese and overweight patients with comorbidities; 44.4% of patients in the surgery and prescription group were extremely or very satisfied, compared with 19.7% among those in the modification group. Treatment satisfaction did not significantly vary between patients using a prescription and those who had surgery.

 

“This finding may mean that diet and exercise alone just don’t work for a lot of people,” said lead investigator Z. Jason Wang, PhD, director of Health Economics and Outcomes at Eisai in Woodcliff Lake, NJ, in a press release. “Drug treatment and bariatric surgical procedures should be considered an integral part of weight management for eligible patients to achieve better treatment satisfaction, which may in turn help patients achieve and maintain better long-term weight loss.”

Previous Post

Rotavirus Vaccination Decreases Diarrhea Hospitalizations Among Kids

Next Post

Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device

Related Posts

Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Next in Pharma 2025 Innovations
Articles

Next in Pharma 2025: Innovations Shaping the Future

28th May 2025
Insights

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

27th May 2025
Insights

AstraZeneca Eyes Acquisition To Develop Cell Therapies

24th March 2025
Drug Development

Continuous Bioprocessing Market to Surge by 2028

7th March 2025
Next Post

Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In